Hematologic dysfunction in cancer: Mechanisms, effects on antitumor immunity, and roles in disease progression
With the major advances in cancer immunology and immunotherapy, it is critical to consider that most immune cells are short-lived and need to be continuously replenished from hematopoietic stem and progenitor cells. Hematologic abnormalities are prevalent in cancer patients, and many ground-breaking...
Main Authors: | Viktoria Plackoska, Dania Shaban, Anastasia Nijnik |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1041010/full |
Similar Items
-
PU.1 is required to restrain myelopoiesis during chronic inflammatory stress
by: James S. Chavez, et al.
Published: (2023-06-01) -
Myelopoiesis during Solid Cancers and Strategies for Immunotherapy
by: Tyler J. Wildes, et al.
Published: (2021-04-01) -
Hematopoietic Progenitors and the Bone Marrow Niche Shape the Inflammatory Response and Contribute to Chronic Disease
by: Yangsong Xu, et al.
Published: (2022-02-01) -
Zebrafish: a convenient tool for myelopoiesis research
by: Yang-Xi Hu, et al.
Published: (2023-01-01) -
Wdr5 is essential for fetal erythropoiesis and hematopoiesis
by: Lulu Liu, et al.
Published: (2023-04-01)